Massachusetts Eye and Ear Infirmary
120
21
28
52
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
23.3%
28 terminated/withdrawn out of 120 trials
65.0%
-21.5% vs industry average
13%
16 trials in Phase 3/4
65%
34 of 52 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (120)
Oral N-acetylcysteine for Retinitis Pigmentosa
Role: collaborator
Study of Remimazolam for Cataract Surgery
Role: collaborator
Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening
Role: lead
ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty
Role: lead
Simulated Walking With Multiplexing Prism for Field Expansion in Monocular Vision
Role: lead
ctDNA in Cutaneous Squamous Cell Carcinoma
Role: lead
A Trial of Hydrus Microstent Versus Goniotomy
Role: lead
Subconjunctival Humira for Boston Keratoprosthesis
Role: lead
FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial
Role: lead
Clinical Trial of Multi-Periscopic Prism Glasses for Hemianopia
Role: lead
Assessment of Corneal Endothelial Function Following Hypoxic Stress
Role: lead
Lactiplantibacillus Plantarum 299v Probiotic Supplementation in Patients With Diabetic Macular Edema
Role: lead
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
Role: lead
Testing Effectiveness of a Stochastic Noise Stimulator to Immediately Improve Balance and Gait
Role: lead
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
Role: lead
Anti-VEGF Therapy for Acute Thyroid Eye Disease
Role: lead
Closed-loop Rehabilitation for Hyperactive Hearing
Role: lead
Tracking Biomarkers of Speech Intelligibility
Role: lead
Study of Aspirin in Patients With Vestibular Schwannoma
Role: lead
Polarization Sensitive Optical Coherence Tomography (PS-OCT) for Retinal Imaging
Role: collaborator